Efficacy and Safety of Paclitaxel/nab-paclitaxel Chemotherapy for Patients With Relapsed Small Cell Lung Cancer.
Yohei MatsuiTadaaki YamadaKenji MorimotoYuki KatayamaOsamu HiranumaShinsuke ShiotsuNobuyo TamiyaTakayuki TakedaYoshie MorimotoMasahiro IwasakuShinsaku TokudaKoichi TakayamaPublished in: Anticancer research (2022)
Treatment with PTX or nab-PTX is effective and tolerable for patients with relapsed SCLC, including those with interstitial lung disease. Our observations suggest that pretreatment inflammatory and nutritional indices may be useful biomarkers for treatment with PTX or nab-PTX.
Keyphrases
- interstitial lung disease
- systemic sclerosis
- advanced non small cell lung cancer
- acute lymphoblastic leukemia
- acute myeloid leukemia
- multiple myeloma
- diffuse large b cell lymphoma
- hodgkin lymphoma
- rheumatoid arthritis
- idiopathic pulmonary fibrosis
- single cell
- oxidative stress
- chemotherapy induced
- cell therapy
- squamous cell carcinoma
- epidermal growth factor receptor
- stem cells
- radiation therapy
- rectal cancer